发明名称 Sustained release pharmaceutical composition
摘要 A sustained release apparatus including a plurality of sustained release mini-implants or pellets; each mini-implant including: a sustained release support material; and a pharmaceutically active composition carried in or on the sustained release support material; the pharmaceutically active composition including: at least one pharmaceutically active component; and a carrier therefore; each implant being of insufficient size and/or payload individually to provide a predetermined desired threshold blood level of pharmaceutical active for treatment of a selected indication; the size(s) of the mini-implants or pellets providing zero order release of pharmaceutical active; the sustained release apparatus providing, in use, zero order release of pharmaceutically active at, or above, the desired threshold level of pharmaceutical active treatment of a selected indication, is disclosed. A sustained release kit is also disclosed. The described sustained release mini-implants or pellets are useful in the manufacture of a sustained release delivery apparatus for the therapeutic or prophylactic treatment of a disease condition in an animal. A method for the therapeutic or prophylactic treatment of a disease condition in an animal (not including a human) requiring such treatment, which method includes administering to the animal a sustained release delivery apparatus as described above is also disclosed.
申请公布号 NZ529859(A) 申请公布日期 2005.11.25
申请号 NZ20020529859 申请日期 2002.07.01
申请人 SMART DRUG SYSTEMS INC 发明人 MARTINOD, SERGE R;BRANDON, MALCOLM
分类号 A61K9/00;A61K9/22;A61K9/30;A61K9/32;A61K9/38;A61K9/52;A61K9/58;A61K31/365;A61K31/7048;A61K38/00;A61K38/18;A61K38/19;A61K38/22;A61K38/43;A61K45/00;A61K47/02;A61K47/12;A61K47/18;A61K47/20;A61K47/24;A61K47/26;A61K47/28;A61K47/30;A61K47/34;A61K47/42;A61P1/04;A61P7/04;A61P29/00;A61P33/02;A61P33/10;A61P35/00;A61P37/06;(IPC1-7):A61K9/58;A61K38/37;A61K39/002;A61K39/02;A61K39/12;A61K39/395;A61K47/48 主分类号 A61K9/00
代理机构 代理人
主权项
地址